United Kingdom is set to carry out a nationwide meningitis vaccine program. The newly designed program will make UK the first country to have a countrywide vaccination.
Jeremy Hunt, health minister of UK, informed that government authorities have finally signed an agreement with GlaxoSmithKline. The pharmaceutical firm has agreed to provide a new meningitis B vaccine for this purpose.
Last year, high health officials announced a similar Bexsero vaccine program for infants. They tried to reach a mutual price point with the vaccine developers but in vain. Sadly, the government had to cancel the program.
Later on, the British government included the vaccine in the national childhood immunization scheme.
In the beginning of March, GlaxoSmithKline acquired majority of the vaccine business of Novartis. The British pharmaceutical firm offered $20 billion to Novartis.
Hunt reported that GSK has significantly cut the price of the vaccine for program. The firm makes it an easier task for government to carry out the planned meningitis B vaccine program.
On the other hand, a spokesperson of GSK informed that the company was quite glad to finalize such kind of an agreement. It is the first achievement of GSK after the purchase of Novartis.
However, the spokesman evidently refused to disclose the terms and conditions of the deal.